137 related articles for article (PubMed ID: 15317602)
41. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
[TBL] [Abstract][Full Text] [Related]
42. Glycaemic and insulinaemic responses to a new hydrogenated starch hydrolysate in healthy and type 2 diabetic subjects.
Rizkalla SW; Luo J; Wils D; Bruzzo F; Slama G
Diabetes Metab; 2002 Nov; 28(5):385-90. PubMed ID: 12461475
[TBL] [Abstract][Full Text] [Related]
43. Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function?
Major-Pedersen A; Ihlemann N; Hermann TS; Christiansen B; Kveiborg B; Dominguez H; Nielsen D; Rask-Madsen C; Svendsen OL; Køber L; Torp-Pedersen C
Horm Metab Res; 2008 Sep; 40(9):607-13. PubMed ID: 18792871
[TBL] [Abstract][Full Text] [Related]
44. Effects of Fuscoporia obliqua on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients.
Maenaka T; Oshima M; Itokawa Y; Masubuchi T; Takagi Y; Choi JS; Ishida T; Gu Y
J Tradit Chin Med; 2008 Mar; 28(1):49-57. PubMed ID: 18416085
[TBL] [Abstract][Full Text] [Related]
45. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
[TBL] [Abstract][Full Text] [Related]
46. Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: results of glucose loading on 2 consecutive days.
Mori Y; Mamori S; Tajima N
Diabetes Obes Metab; 2005 Mar; 7(2):182-8. PubMed ID: 15715891
[TBL] [Abstract][Full Text] [Related]
47. High-polyphenol chocolate reduces endothelial dysfunction and oxidative stress during acute transient hyperglycaemia in Type 2 diabetes: a pilot randomized controlled trial.
Mellor DD; Madden LA; Smith KA; Kilpatrick ES; Atkin SL
Diabet Med; 2013 Apr; 30(4):478-83. PubMed ID: 23039340
[TBL] [Abstract][Full Text] [Related]
48. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
[TBL] [Abstract][Full Text] [Related]
49. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.
Choudhury S; Hirschberg Y; Filipek R; Lasseter K; McLeod JF
J Clin Pharmacol; 2000 Jun; 40(6):634-40. PubMed ID: 10868314
[TBL] [Abstract][Full Text] [Related]
50. Non-invasive assessment of vascular function; paradoxical vascular response to intravenous glucose in coronary heart disease.
Leyva F; Rauchhaus M; Anker SD; Proudler AJ; Godsland IF; Stiefel P; Coats AJ; Poole-Wilson PA; Stevenson JC
Eur Heart J; 2000 Jan; 21(1):39-44. PubMed ID: 10610742
[TBL] [Abstract][Full Text] [Related]
51. [Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
MMW Fortschr Med; 2002 May; 144(21):58. PubMed ID: 12134432
[No Abstract] [Full Text] [Related]
52. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R
Endocr J; 2000 Oct; 47(5):639-41. PubMed ID: 11200947
[TBL] [Abstract][Full Text] [Related]
53. [NAVIGATOR trial (nateglinide)].
Tsujii S
Nihon Rinsho; 2005 Feb; 63 Suppl 2():483-7. PubMed ID: 15779426
[No Abstract] [Full Text] [Related]
54. Effect of 10 days of bedrest on metabolic and vascular insulin action: a study in individuals at risk for type 2 diabetes.
Sonne MP; Alibegovic AC; Højbjerre L; Vaag A; Stallknecht B; Dela F
J Appl Physiol (1985); 2010 Apr; 108(4):830-7. PubMed ID: 20110547
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
Inoue T; Shibahara N; Miyagawa K; Itahana R; Izumi M; Nakanishi T; Takamitsu Y
Clin Nephrol; 2003 Aug; 60(2):90-5. PubMed ID: 12940610
[TBL] [Abstract][Full Text] [Related]
56. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
Hirose T; Mizuno R; Yoshimoto T
Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
[TBL] [Abstract][Full Text] [Related]
57. Nateglinide.
Dunn CJ; Faulds D
Drugs; 2000 Sep; 60(3):607-615; discussion 616-7. PubMed ID: 11030470
[TBL] [Abstract][Full Text] [Related]
58. Comparison of effects of α-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease.
Sawada T; Shiotani H; Terashita D; Nagasawa Y; Kim SS; Koide M; Yokoyama M
Circ J; 2014; 78(1):248-55. PubMed ID: 24225338
[TBL] [Abstract][Full Text] [Related]
59. [Therapy of type 2 diabetes. Effective control of postprandial glucose surges].
MMW Fortschr Med; 2001 Jul; 143(28-29):56-7. PubMed ID: 11499153
[No Abstract] [Full Text] [Related]
60. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A
Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
